- Home
- NERV
as 12-18-2024 4:00pm EST
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 18.3M | IPO Year: | 2014 |
| Target Price: | $5.00 | AVG Volume (30 days): | 14.3K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.06 - $13.49 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Minerva Neurosciences Inc News
NERV Breaking Stock News: Dive into NERV Ticker-Specific Updates for Smart Investing
Associated Press Finance
a month ago
Minerva Neurosciences: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Associated Press Finance
4 months ago
Minerva Neurosciences: Q2 Earnings Snapshot
GlobeNewswire
4 months ago
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
CNW Group
6 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
6 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
6 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
6 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Compare NERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NERV Minerva Neurosciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.